UNSPSC 51401554: Tetrazepam

This classification denotes a benzodiazepine with the molecular formula C16H17ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FO92091VP8, chemically known as 7-chloro-5-(cyclohexen-1-yl)-1,3-dihydro-1-methyl-2h-1,4-benzodiazepin-2-one but generally known as tetrazepam, which bears US NIH Compound Identifier 25215. European Medicines Agency schedules Tetrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10946MIG. The term TETRAZEPAM is an International Non-Proprietary Name.

UNSPSC 51401554 Tetrazepam, a Commodity code, nominally covers a single pharmaceutical product, but the recent state and local opportunities posted under this code actually span a much broader procurement activity: acquisition of multiple pharmaceutical products, naloxone kits, drug deactivation systems, and generic multi-source OTC medications through both direct purchase and cooperative contracting vehicles. State and local governments are using this code to solicit routine pharmaceutical supply agreements for community health programs, emergency response capabilities, and multi-jurisdictional pharmacy benefit programs. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local members (Minnesota Multistate Cooperative Purchasing Alliance, with participation from Oregon and other states). The scope reflects operational purchasing of medications and health-related supplies rather than a single narrow product line.

Recent activity centers on the Upper South, Upper Midwest, and Texas. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to Sanford, Florida and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer pharmaceutical prescriptions outside traditional PBM and GPO channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness of July 1, 2026; this vehicle is a multi-award cooperative agreement covering authorized wholesalers and requiring vendors to maintain cGMP and DSCSA compliance. The code shows active procurement activity but with only three recent opportunities, all posted within the past seven months, suggesting moderate seasonal activity rather than continuous sourcing.